Trials / Completed
CompletedNCT07168655
Mavacamten in Obstructive Hypertrophic Cardiomyopathy
Real-World Patients With Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten - a Single-Center Descriptive Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 163 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the real-world outcomes of individuals diagnosed with obstructive hypertrophic cardiomyopathy (oHCM) treated with mavacamten at the Hospital of The University of Pennsylvania in the US
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mavacamten | According to the product label |
Timeline
- Start date
- 2023-02-21
- Primary completion
- 2023-03-31
- Completion
- 2025-03-25
- First posted
- 2025-09-11
- Last updated
- 2025-09-11
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07168655. Inclusion in this directory is not an endorsement.